Literature DB >> 12017411

Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases.

Lori Frank1, Leah Kleinman, Anne Rentz, Gabrielle Ciesla, John J Kim, Christopher Zacker.   

Abstract

BACKGROUND: Despite the rapidly growing body of literature on health-related quality of life (HRQoL). placing the results in a context that is meaningful to clinicians and patients is often overlooked.
OBJECTIVE: This study sought to quantify the impact of irritable bowel syndrome (IBS) on HRQoL by comparing the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) scores of IBS patients with normative US data and with the scores of patients having other chronic gastrointestinal (GI) and non-GI disorders.
METHODS: Two IBS reference groups were identified from the published literature: a largely untreated community sample of health maintenance organization (HMO) members (N = 92) and a sample of patients with IBS recruited through clinics and in the community (N = 140). SF-36 scores for these groups were compared with published US population norms (N = 2474) and with published scores for 3 other IBS samples (N = 464); a sample with other chronic GI disorders (dyspepsia [N = 126], gastroesophageal reflux disease [GERD] [N = 516]); and samples with other chronic episodic disorders (asthma [N = 375], migraine [N = 303], panic disorder [N = 73], rheumatoid arthritis [N = 693]).
RESULTS: The scores of patients in both IBS reference groups were significantly lower on several SF-36 domains than those of the US normative population (P < 0.003). Scores on several SF-36 scales were also significantly lower in the IBS reference groups compared with the GERD, asthma, and migraine samples (P < 0.003). Depending on the IBS sample used, scores did not differ or were higher compared with those in the sample with dyspepsia. Relative to the samples with panic disorder and rheumatoid arthritis, the IBS groups had significantly higher scores on most SF-36 domains (P < 0.003). Scores for the HMO reference group were generally higher than those for the clinic/community reference group.
CONCLUSIONS: Based on the results of this analysis, IBS is associated with impairment of HRQoL relative to US population norms and to populations with GERD, asthma, or migraine. HRQoL appears to be greater in patients with IBS than in those with panic disorder or rheumatoid arthritis, although the relative symptom severity in these samples was not known.

Entities:  

Mesh:

Year:  2002        PMID: 12017411     DOI: 10.1016/s0149-2918(02)85143-8

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  71 in total

1.  What level of IBS symptoms drives impairment in health-related quality of life in community subjects with irritable bowel syndrome? Are current IBS symptom thresholds clinically meaningful?

Authors:  Natasha A Koloski; Philip M Boyce; Michael P Jones; Nicholas J Talley
Journal:  Qual Life Res       Date:  2011-08-11       Impact factor: 4.147

2.  Linaclotide: a novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome.

Authors:  Brian E Lacy; John M Levenick; Michael D Crowell
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-10

3.  The treatment of irritable bowel syndrome.

Authors:  Brian E Lacy; Kirsten Weiser; Ryan De Lee
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

4.  Treatment effects of partially hydrolyzed guar gum on symptoms and quality of life of patients with irritable bowel syndrome. A multicenter randomized open trial.

Authors:  Giancarlo Parisi; Enrico Bottona; Maurizio Carrara; Fabrizio Cardin; Alessandra Faedo; Dario Goldin; Marco Marino; Maurizio Pantalena; Gianni Tafner; Giorgio Verdianelli; Maurizio Zilli; Gioacchino Leandro
Journal:  Dig Dis Sci       Date:  2005-06       Impact factor: 3.199

Review 5.  Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment.

Authors:  P Paré; Ronald Bridges; Malcolm C Champion; Subhas C Ganguli; James R Gray; E Jan Irvine; Victor Plourde; Pierre Poitras; Geoffrey K Turnbull; Paul Moayyedi; Nigel Flook; Stephen M Collins
Journal:  Can J Gastroenterol       Date:  2007-04       Impact factor: 3.522

Review 6.  New treatments for irritable bowel syndrome in women.

Authors:  Mopelola A Adeyemo; Lin Chang
Journal:  Womens Health (Lond)       Date:  2008-11

Review 7.  Global burden of irritable bowel syndrome: trends, predictions and risk factors.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-15       Impact factor: 46.802

8.  Ambivalence over emotional expression and perceived social constraints as moderators of relaxation training and emotional awareness and expression training for irritable bowel syndrome.

Authors:  Hannah J Holmes; Elyse R Thakur; Jennifer N Carty; Maisa S Ziadni; Heather K Doherty; Nancy A Lockhart; Howard Schubiner; Mark A Lumley
Journal:  Gen Hosp Psychiatry       Date:  2018-05-03       Impact factor: 3.238

9.  Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients.

Authors:  Helen M Pettinati; David R Gastfriend; Qunming Dong; Henry R Kranzler; Stephanie S O'Malley
Journal:  Alcohol Clin Exp Res       Date:  2008-11-25       Impact factor: 3.455

10.  Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome.

Authors:  Tisha N Lunsford; Lucinda A Harris
Journal:  Int J Womens Health       Date:  2010-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.